Immorta Bio Reports Preclinical Activity of Senolytic Immunotherapy SenoVax™ in a Chronic Traumatic Encephalopathy (CTE) Model

Newly filed patent describes an unexpected senescence–CTE link; SenoVax™-induced antibodies showed strongest effects among senolytics tested

MIAMI, Sept. 24, 2025 /PRNewswire/ -- Immorta Bio, Inc., a scientific longevity company focused on "Treating Diseases of Aging and Treating Aging as Disease™," today announced the filing of a U.S. patent application covering unexpected preclinical findings that senolytic approaches—including the company's senolytic immunotherapy SenoVax™—improved outcomes in experimental models of chronic traumatic encephalopathy (CTE).

CTE is a progressive neurodegenerative condition associated with repetitive head impacts in athletes, military veterans, and others. It is characterized by mood and behavior changes (e.g., depression, irritability), cognitive decline, and can progress to dementia. There are currently no approved disease-modifying treatments.

"Our data suggest that cellular senescence is a driver of CTE-related inflammation and brain injury," said Thomas E. Ichim, PhD, President and Chief Scientific Officer of Immorta Bio. "In preclinical models, senolytic strategies reduced CTE-associated signals, with antibodies generated by SenoVax™ showing the most pronounced effects among the senolytics we evaluated."

SenoVax™ is a first-in-class senolytic immunotherapy that trains the immune system to clear senescent 'zombie' cells implicated in cancer immune evasion and aging. In oncology models, SenoVax™ has shown tumor control across lung, breast, glioma, and pancreatic settings, synergy with checkpoint inhibitors, and immune rejuvenation signals (CD8/NK activity). Immorta Bio has filed an IND to begin clinical evaluation of SenoVax™ in advanced non–small cell lung cancer (NSCLC) and is working with the FDA on a defined GMP demonstration run as the remaining step prior to IND clearance.

"Seeing our cancer immunotherapy show promise in a neurologic, trauma-linked disease underscores how longevity science can unlock cross-disciplinary therapies," said Boris N. Reznik, PhD, Chairman and CEO of Immorta Bio. "We're pressing forward to open our lung cancer trial and, in parallel, systematically explore CTE and other neurodegenerative indications."

About Immorta Bio

Immorta Bio, Inc. is a longevity-focused biotechnology company developing personalized cellular and immune therapeutics, including SenoVax™ (senolytic immunotherapy) and StemCellRevivify™ (personalized cellular rejuvenation and exosomes). Learn more at immortabio.com.

Media & Investor Contact
Immorta Bio, Inc.
+1 (305) 632-2939
401668@email4pr.com

Forward-Looking Statements: This press release contains forward-looking statements, including statements regarding the development, regulatory status, and potential benefits of SenoVax™ and other programs, and potential applications in CTE. Actual results may differ materially due to risks and uncertainties inherent in drug discovery, preclinical, and clinical development, manufacturing, regulatory review, financing, and market conditions. SenoVax™ has not been approved for any indication, and the CTE findings are preclinical. Immorta Bio undertakes no obligation to update these statements

View original content to download multimedia:https://www.prnewswire.com/news-releases/immorta-bio-reports-preclinical-activity-of-senolytic-immunotherapy-senovax-in-a-chronic-traumatic-encephalopathy-cte-model-302565883.html

SOURCE Immorta Bio, Inc.